Connect with us

Emerging Markets

Cryomass Technologies Inc (OTCMKTS: CRYM) on the Move as Co Completes Testing of CryoCann 500 CF & Prepares to Deliver First Commercial Unit

Published

on

Cryomass Technologies Inc (OTCMKTS: CRYM) has been making an explosive move up the charts in recent trading after the Company reported rigorous testing of its patented cryogenic trichrome separation system has yielded results in all key areas of interest that either met or significantly surpassed pre-testing expectations.  The Company is now busily preparing to deliver its first commercial unit to an operating partner based in the heart of the largest cannabis production region of the world’s largest cannabis market, California. This Monterey-based company manufactures premium extracts for their own brand and several of the more prominent, better-known brands in California.  Their extensive expertise in producing high-quality, standardized extracts should prove invaluable as we refine standard operating procedures (SOP) to guide product development for future customers. CRYM is establishing a toll processing station at their sophisticated Monterey facility, where the Company expects to process cannabis on behalf of some of California’s leading cannabis cultivators, many of which are already close business relationships.  CRYM is confident this partnership will begin generating revenues in the 4th quarter of 2022 and anticipate a steep ramp-up in revenues throughout 2023. 

CRYM has a long history of making big moves off its $0.20 base including running to hit a high of $0.64 last year followed by several months of choppy waters, another test of $0.20 support and a recent runup to $0.54. Now that CRYM is once again on the move surpassing $0.30 on Friday investors are quickly catching on to this story. CRYM trades at a very reasonable market valuation with OS at  201,478,332 and 88,737,648 shares in the float. CRYM is a sec filer and fully reporting OTCQB venture exchange Company that recently completed a $10.3 million equity financing. The Company has a strong balance sheet with $3,667,453, just $1.5 million in debt and $13,326,693 in total assets.  

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Cryomass Technologies Inc (OTCMKTS: CRYM) owner of superior, patented technology is building out its industry shattering CryoCann 500 CF for the handling of harvested cannabis, hemp and other high-value plant material. The company owns patented technology that utilizes liquid nitrogen to fully separate, collect and protect the high-value materials and essential compounds from the harvested plant. Building on that technology, the company’s technical team has completed an initial design for the CryoCann 500 CF system. The CryoCann 500 CF is optimized for the rapid capture (within minutes after plant harvesting) of fully intact cannabis and hemp trichomes, as well as terpenes. Rapid capture should enable cannabis and hemp producers to dramatically reduce costs, increase end-product yields and enhance product purity. The resulting sift can be warehoused for extended periods, or further processed into consumer products. The company believes that efficiencies delivered by the CryoCann 500 CF will trigger industry-wide changes in the handling and processing of harvested cannabis and hemp. It also is exploring the application of the underlying technology to a broad range of industries that handle high-value materials that could benefit from precision capture methods. 

CryoMass Technologies | Refinement Systems for Cannabis and HempThe CryoMass Refinement System uses patented technology to instantly freeze the whole plant and fully separates the trichomes, including THC, CBD and terpenes, from the biomass. The patented process renders up to a 90% dried output material with a dramatic reduction in biomass volume of up to 80%. The resulting high purity, refined “cryogenic sift” can be warehoused for extended periods of time or further processed into cannabis and hemp distillate or isolate for use in consumer products. 

Recently CRYM was granted a patent by the Canadian Intellectual Property Office (#3064896) for its novel plant material separation process technology.  The patent relates in general to separating plant particulates and, in particular, to a system and method for cryogenic separation of plant material.  The patent will remain valid until 2039. The Canadian patent follows the precedent set by the United States Patent and Trademark Office and the State Intellectual Property Office of the P. R. of China, both of which granted process patents to CryoMass that are valid until 2038. CryoMass remains committed to expanding its global patent protection portfolio and is pursuing patents in other important jurisdictions, including the European Union. 

To Find out the inside Scoop on CRYM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

CRYM

On August 4 CRYM announced rigorous testing of its patented cryogenic trichrome separation system has yielded results in all key areas of interest that either met or significantly surpassed pre-testing expectations.  The Company is now busily preparing to deliver its first commercial unit to an operating partner based in the heart of the largest cannabis production region of the world’s largest cannabis market, California. This Monterey-based company manufactures premium extracts for their own brand and several of the more prominent, better-known brands in California.  Their extensive expertise in producing high-quality, standardized extracts should prove invaluable as we refine standard operating procedures (SOP) to guide product development for future customers. CRYM is establishing a toll processing station at their sophisticated Monterey facility, where the Company expects to process cannabis on behalf of some of California’s leading cannabis cultivators, many of which are already close business relationships.  CRYM is confident this partnership will begin generating revenues in the 4th quarter of 2022 and anticipate a steep ramp-up in revenues throughout 2023. 

CryoMass Technologies | Refinement Systems for Cannabis and HempThe CryoMass system enables cannabis and hemp cultivators and processors to optimize and streamline their processes, thus dramatically reducing costs while simultaneously capturing approximately 97% of the active elements and increasing the purity and quality of the products sold to consumers. 

CryoMass Director and CEO Christian Noël stated, “Finally, after seven years of engineering, product development, and testing, we are ready to commercialize this exciting new technology.  And the demand is incredible.  Every week we receive inquiries from cannabis and hemp cultivators and processors from all around the United States and the rest of the world as well.  It’s an exciting time for us. Our initial target market is North America, especially the United States.  We think our first deployment in Monterey will serve to attract cultivators from within a four-hour radius seeking to avail themselves of this “must-have” new cryogenic trichome separation technology.  Between Santa Barbara and Monterey, we will be positioned to toll-process for approximately 5,000 cultivation licenses representing 60% of the entire California market.  We view this first installation as the perfect venue to showcase the CryoMass system to future customers from all around the globe.” 

It is important to note that one of the key reasons the CryoMass system is so much more efficient from a process and cost-saving perspective is that it is the only continuous-feed separation system while all others are batch-feed systems. Although the Company’s initial focus is on the cannabis and hemp sector, there is tremendous potential to generate important revenue streams from processing other high-value, trichrome-rich plants where similar cost savings and end-product improvements can be realized. 

For More on CRYM Subscribe Right Now!

Currently trading at a $59 million market cap CRYM has 200,435,331 shares outstanding 114,173,042 of which are restricted with just 88,737,648 shares in the float. CRYM is a sec filer and fully reporting OTCQB venture exchange Company that recently completed a $10.3 million equity financing. The Company has a strong balance sheet with $3,667,453, just $1.5 million in debt and $13,326,690 in total assets. CRYM recently completed rigorous testing of its patented cryogenic trichrome separation system has yielded results in all key areas of interest that either met or significantly surpassed pre-testing expectations.  The Company is now busily preparing to deliver its first commercial unit to an operating partner based in the heart of the largest cannabis production region of the world’s largest cannabis market, California. This Monterey-based company manufactures premium extracts for their own brand and several of the more prominent, better-known brands in California.  Their extensive expertise in producing high-quality, standardized extracts should prove invaluable as we refine standard operating procedures (SOP) to guide product development for future customers. CRYM is establishing a toll processing station at their sophisticated Monterey facility, where the Company expects to process cannabis on behalf of some of California’s leading cannabis cultivators, many of which are already close business relationships.  CRYM is confident this partnership will begin generating revenues in the 4th quarter of 2022 and anticipate a steep ramp-up in revenues throughout 2023.  We will be updating on CRYM when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CRYM.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in CRYM either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Emerging Markets

Lucy Scientific Discovery’s (NASDAQ: LSDI) Game-Changing Move: A Closer Look at the High Times Acquisition

Published

on

On August 8th, 2023, Lucy Scientific Discovery Inc. (NASDAQ: LSDI), a leading developer in the psychedelic drug industry, witnessed an impressive surge in its stock value, gaining approximately 25% in combined trading, including after-hours (AH) trading. The British Columbia-based company made headlines by announcing its strategic move to acquire intellectual property (IP) from the renowned cannabis publication, High Times Holding Corp. (HHC).

Additional Background:

Under this agreement, Lucy will exchange 20% of its shares and a series of payments for access to HHC’s valuable IP portfolio, which includes the rights to generate licensing and royalty income from renowned brands like High Times, 420.com, and Cannabis Cup, along with their associated domain names.

Lucy’s commitment involves making semi-annual payments to HHC over a five-year period, structured around earnings before income, taxes, depreciation, and amortization (EBITDA) generated through the acquired IP. The flexibility exists for Lucy to fulfill these payments either in cash or through stock issuance and the announcement is generating considerable interest.

Furthermore, post-acquisition, Lucy will grant High Times the opportunity to operate retail outlets and distribute THC products bearing these prestigious brands within the United States. This privilege comes in exchange for an annual license fee of $1 million, set to double to $2 million annually once federal legalization of cannabis occurs in the country.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Leveraging the brand rights secured from HHC, Lucy aims to bolster its revenue streams by expanding and enhancing its existing 18 licensing agreements, both domestically and internationally. These arrangements encompass a wide array of consumer products and merchandise, promising to further establish Lucy’s presence in the global market. The acquisition is expected to be finalized within the coming two weeks, marking a significant strategic move for Lucy Scientific Discovery Inc.

As a result of the acquisition, High Times is now a publicly-traded entity. Lucy anticipates that this agreement will contribute over $10 million in revenue to its financial results in the upcoming year, along with $5 million in EBITDA.

Adam Levin, the Executive Chairman of HHC, expressed optimism about the deal, noting, “This transaction will create exciting new growth opportunities for the High Times brand, under the leadership of Richard Nanula, a seasoned executive with extensive experience in major consumer brands and global corporations.”

Levin also emphasized High Times’ enthusiasm in becoming a significant shareholder of Lucy Scientific Discovery. Notably, Lucy completed its initial public offering and Nasdaq listing in February, offering 1,875,000 shares at $4.00 each.

Richard Nanula, CEO of the British Columbia-based company, shared his outlook on the acquisition, stating, “Lucy expects this acquisition to rapidly generate high-margin revenue within the global cannabis sector.”

In recent developments, Lucy introduced the sleep aid product “Twilight,” which includes amanita muscaria and reishi mushrooms. Additionally, the company joined forces with Wesana Health Holdings Inc. (OTCQB: WSNAF) in March to collaborate on the development of the CBD and psilocybin-based drug SANA-013, targeting conditions such as migraines, cluster headaches, and major depressive disorder.

High Times, founded in 1974, has a rich history, featuring works by renowned writers like Truman Capote and Hunter S. Thompson. Since 1988, its Cannabis Cup has stood as the most prestigious cannabis competition globally, with notable judges including Snoop Dogg, Joe Rogan, Tommy Chong, and other prominent figures in the cannabis industry.

While Lucy’s shares showed a nearly 16% increase to reach $0.68 on the Nasdaq exchange on Friday, it is worth noting that they have experienced a decline of over 77% over the past year.

Macro Trend:

In recent times, our articles have prominently featured cannabis-related topics, reflecting the growing popularity of stocks in this sector. LSDI’s acquisition aligns perfectly with the current climate, as the cannabis industry experiences a significant surge, coinciding with the Health and Human Services (HHS) exploring the possibility of reclassifying cannabis from Schedule I to Schedule III of the Controlled Substances Act.

While many countries around the world have already moved towards decriminalization and legalization, the United States has been relatively cautious in its approach. However, the consideration of such a reclassification represents a potential historic turning point. If such a change were to materialize, it would mark a substantial shift in the regulatory landscape, potentially revitalizing cannabis as an attractive investment opportunity. The industry is already showing signs of reestablishing its market presence and could once again become a noteworthy investment option.

We will update you on LSDI when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by herbalhemp from Pixabay

 

Continue Reading

Emerging Markets

WM Technology’s (NASDAQ: MAPS) Stock Surges 91% in Mysterious Rally: What’s Behind the Boom?

Published

on

WM Technology’s (NASDAQ: MAPS) stock has exhibited remarkable growth, surging by an impressive 91% since August 16th, 2023. Intriguingly, this surge occurred in the absence of any substantial news or filings from the company, with their most recent release dating back to August 23rd, 2023. This limited information raises the question: What is driving this impressive rally? We will delve into the details below to shed light on the matter.

Cannabis Industry:

If you’ve been following our newsletter, you may have noticed our recent article spotlighting Flora Growth Corp. (NASDAQ: FLGC), along with larger players like Cronos Group Inc. (NASDAQ: CRON), and Canopy Growth Corporation (NASDAQ: CGC).

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In case you haven’t had a chance to read it, you can find the article here, featuring a dedicated section on the broader trends shaping the cannabis industry.

For those seeking a quick summary, a significant development has emerged in the cannabis landscape. A high-ranking official at the Department of Health and Human Services (HHS) has proposed moving cannabis from Schedule I to Schedule III of the Controlled Substances Act. This shift marks a historic moment and comes after a comprehensive yearlong investigation requested by President Biden.

It’s worth noting the potential implications of this change for U.S.-based, plant-touching marijuana companies. Currently, these companies are restricted from trading on major exchanges like the NYSE or NASDAQ and are relegated to smaller markets such as the OTC, or smaller Canadian markets like the TSX, CSE, or NEO.

The CEO of Trulieve Cannabis Corp. (OTC: TCNNF), Kim Rivers delves into these implications in a podcast conversation with a Twitter user known as @stock_mj. She also recommends keeping a close eye on the AdvisorShares Pure US Cannabis ETF (MSOS) as the cannabis sector garners increasing attention from investors.

Weedmap’s Earnings:

To evaluate the potential of MAPS, it’s essential to examine their recent earnings and assess the fundamentals. Here’s a brief overview of the news release.

Revenue: Amounted to $50.9 million, representing a decline compared to the same period in the prior year when it reached $58.3 million.

Net Income: Recorded at $2.0 million for the second quarter of 2023, marking a significant decrease from the previous year’s figure of $19.8 million.

Adjusted EBITDA: Showed substantial improvement, totaling $10.2 million in the second quarter of 2023, as opposed to a negative figure of $(0.6) million in the same period of the prior year.

Cash: As of June 30, 2023, the company held $24.6 million in cash, noteworthy for being entirely debt-free.

WM Technology’s Executive Chair, Doug Francis, underscored the company’s dedication to reinforcing its financial position and delivering sustained growth.

Guidance for the third quarter of 2023:

Revenue: An estimated $47 million.

Non-GAAP Adjusted EBITDA: Approximately $4 million.

It’s important to note that these projections are subject to potential variations based on various factors and developments.

Furthermore, WM Technology announced the transition to Moss Adams LLP as its new independent registered public accounting firm, effective upon the filing of the Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, following the resignation of Baker Tilly US, LLP due to staffing constraints.

Although the company maintains a debt-free status, it’s crucial to recognize that there has been a substantial decline in both revenue and net income. Consequently, it is advisable to exercise caution when considering investment, as the current trajectory of their top-line figures does not exhibit a positive trend.

https://twitter.com/5teelersfan/status/1699102436672299134?s=20

Weedmap’s Strategic Partnership:

Furthermore, the company made another recent announcement regarding its strategic partnership with the producer of “The Freak Brothers,” a celebrated stoner comic series that has captivated audiences for over five decades.

The series follows the adventures of three stoner characters and their cat, who awaken from a 50-year slumber induced by a magical strain of weed in 1969, now navigating life in contemporary San Francisco.

Key highlights of this partnership include in-episode Weedmaps integrations in the upcoming second half of “Freak Brothers” season two, commencing on September 24th. Additionally, exclusive “Smoke & Screen” events will be held across the U.S., bringing together influential figures from both the cannabis and entertainment industries.

“The Freak Brothers” series, based on Gilbert Shelton’s cult classic comic, celebrates its 55th anniversary with a star-studded voice cast for Season 2, featuring Woody Harrelson, John Goodman, Pete Davidson, Tiffany Haddish, Adam Devine, Blake Anderson, Andrea Savage, La La Anthony, ScHoolboy Q, and a special guest appearance by Joe Sikora.

To watch Season 2 of “The Freak Brothers,” visit Tubitv.com, and for cannabis-related information, explore Weedmaps.com. For more on “The Freak Brothers,” visit the official website at www.thefreakbrothers.com.

We will update you on MAPS when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by NickyPe from Pixabay.com

Continue Reading

Emerging Markets

Cannabis Industry Surges: Flora Growth Corp. (NASDAQ: FLGC) Leads the Way with 77% Intraday Jump

Published

on

Flora Growth Corp. (NASDAQ: FLGC) experienced a remarkable intraday surge of over 77%. While the company has made significant announcements recently, today’s surge occurred without any specific filings or press releases to explain it. There seems to be something substantial driving this trading frenzy, a broader force impacting the entire asset class.

It’s worth noting that established industry leaders like Canopy Growth Corporation (NASDAQ: CGC) and Cronos Group Inc. (NASDAQ: CRON) have faced significant downtrends in past years. However, today’s market activity also lifted their stocks along with others. To understand this trend, let’s take a closer look at the larger market dynamics at play.

 

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What Happened:

A top official at the Department of Health and Human Services (HHS) has recommended moving cannabis from Schedule I to Schedule III of the Controlled Substances Act, marking a historic shift. This move follows a comprehensive yearlong investigation requested by President Biden.

https://twitter.com/NotFinancialRep/status/1697189406665245149?s=20

In the short term, this won’t significantly impact the cannabis industry, as the Drug Enforcement Agency (DEA) needs to conduct its own review and the federal prohibition on marijuana remains. However, the HHS recommendation, if followed by the DEA, could happen within a year, possibly before the 2024 presidential election.

Long-term implications for the cannabis industry are uncertain, but a key immediate effect would be the elimination of Section 280e of the IRS tax code for cannabis businesses. This provision currently prevents them from claiming standard business deductions, a major financial burden.

While rescheduling won’t directly open up access to institutional banking, it may attract new capital sources due to reduced risk perception among investors. Smaller banks and lenders might become more willing to engage.

Eliminating 280e could also stimulate lending in an industry with high borrowing costs, as companies would have improved cash flow. This might lead to lower interest rates and greater access to operating and expansion capital.

Rescheduling could benefit publicly traded cannabis companies, potentially enticing more exchanges, like the Toronto Stock Exchange, to accept U.S.-based cannabis businesses. It could also encourage Congress to take further action, such as passing the SAFE Banking Act and broader reforms.

Overall, while the exact implications of rescheduling are uncertain, the HHS announcement signals progress toward a post-prohibition reality for the cannabis industry, which is a significant development.

https://twitter.com/S_Andreoni/status/1697289527180562880?s=20

Having set the stage with the broader cannabis industry context, let’s delve into Flora Growth’s recent developments and their implications for the company’s future. Is Flora Growth strategically positioned to leverage the potential easing of restrictions in the cannabis sector?

European Expansion:

Flora Growth just formed a partnership with TruHC Pharma GmbH, a leading medical cannabis expert based in Hamburg, Germany. TruHC holds key certifications for importing, distributing, and manufacturing medical cannabis and is awaiting an EU-GMP license for its cutting-edge cannabis laboratory.

Hendrik Knopp, a respected legal professional and entrepreneur, and his team from TruHC are joining Flora, bringing their extensive expertise in pioneering medical cannabis in Germany. This partnership is seen as very valuable, especially as Germany and the European Union move towards making medical cannabis more accessible to patients.

Clifford Starke, CEO of Flora, expressed excitement about the collaboration, recognizing the potential to contribute to the growth of the medical cannabis industry as regulations evolve. The partnership aims to capture a significant market share in Germany.

Hulk Hogan Partnership:

Flora Growth also just recently entered an exclusive worldwide partnership with WWE legend Hulk Hogan to launch a range of consumer products through Just Brands. These products will include CBD-infused items like pre-rolls, topicals, edibles, and more, which Flora will produce and sell globally. The partnership aims to capitalize on Hulk Hogan’s iconic status and Flora’s global distribution network. The initial agreement is for three years, with potential renewals, targeting $20 million in sales over the first 24 months. Flora will pay royalties and license fees for Hulk Hogan-branded products.

Conclusion:

In summary, the cannabis industry appears ready for a resurgence, buoyed by renewed investor optimism and shifting market dynamics. Our focus today was Flora Growth Corp. (NASDAQ: FLGC) but larger names like Canopy Growth Corporation (NASDAQ: CGC) and Cronos Group Inc. (NASDAQ: CRON) are among the many companies benefitting from this positive trend.

We will update you on FLGC when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by 7raysmarketing from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.